Methods and compositions for the direct concentrated delivery of passive immunity

• US 5,530,102 A
• Filed: 05/15/1995
• Issued: 06/25/1996
• Est. Priority Date: 01/12/1993
• Status: Expired due to Term

• Current Assignee: London Health Sciences Centre Research Incorporated
• Original Assignee: Anthony G. Gristina, Quentin N. Myrvik
• Inventors: Myrvik, Quentin N., Gristina, Anthony G.
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): LORING, SUSAN
• Application Number:
  US08/441,299
• Time in Patent Office: 407 Days
• Field of Search: 530/391.1, 530/388.4, 604/46, 604/93, 606/76
• US Class Current: 530/391.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: C07K 16/12 against material from bacteria
• CPC Class Codes: C07K 16/1214 from Pseudomonadaceae (F)
• CPC Class Codes: C07K 16/1271 from Micrococcaceae (F), e.g. Staphylococcus
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint. The inventive compositions have particular application in preventing infections.

Claims

1. A biomaterial, comprising:

a device insertable into a human or animal host'"'"'s body at a surgical or trauma site of a wound, burn or biomaterial implant site, said device having a body contacting surface; and

an immunoglobulin composition coated on said surface of said device, said immunoglobulin composition comprising a combination of IgG, IgM and IgA, wherein said composition contains elevated levels of IgM between 200-300 mg/dl and IgA between 400-500 mg/dl when compared with normal serum levels, wherein said immunoglobulin composition is specific for microorganisms.

2. The biomaterial of claim 1, wherein said immunoglobulin composition comprises monoclonal antibodies.

3. The biomaterial of claim 1 wherein said device is selected from the group consisting of contact lenses, catheters, ventilators, vascular grafts, internal fixation devices, and joints.

4. The biomaterial of claim 1 wherein said immunoglobulin composition is immobilized on said surface of said device.

5. The biomaterial of claim 1 further comprising a matrix carrier on said surface of said device wherein said matrix carrier is selected from the group consisting of fibrin, collagen, gelatin, polysaccharides, and hyaluronan.

6. The biomaterial of claim 1, wherein said immunoglobulin composition is specific for at least two microorganisms selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Streptococcus mutans, Bacteroides gingivalis, Streptococcus (Groups A, B and D), Coagulase Negative Staphylococci, Klebsiella pneumoniae, Hemophilus influenzae, Proteus spp., Mycoplasma pneumoniae, Streptococcus pyogenes, Respiratory Syncytial Virus, Influenza Virus (A, B, and C), and rhinoviruses.

7. The biomaterial of claim 6, wherein said immunoglobulin composition comprises monoclonal antibodies.